Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 5/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130262 | 1.00 | CARM1 (0.41) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL10130232 | 1.00 | CARM1 (0.41) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL8085877 | 0.89 | CARM1 (0.52) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL17574703 | 0.88 | SIGMAR1 (0.47) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL13995508 | 0.88 | KDM4E (0.50) | ALDH1A1KDM4EHRH3HTR7 | |
| SCHEMBL17574727 | 0.88 | SIGMAR1 (0.47) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL12449634 | 0.88 | KDM4E (0.50) | ALDH1A1KDM4EHRH3HTR7 | |
| SCHEMBL13077 | 0.88 | KDM4E (0.50) | ALDH1A1KDM4EHRH3HTR7 | |
| SCHEMBL14734013 | 0.82 | CARM1 (0.37) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL13171586 | 0.81 | GBA1 (0.40) | SIGMAR1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-2534152-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
| US-9895443-B2 | Multi-tailed lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895443-B2 | Multi-tailed lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CARM1 988/4885PRMT6 3673/4885PRMT1 2565/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CARM1 988/4885PRMT6 3673/4885PRMT1 2565/4885 |
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CARM1 1598/4885PRMT6 3183/4885PRMT1 2256/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CARM1 1598/4885PRMT6 3183/4885PRMT1 2256/4885 |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | CARM1 3347/4885PRMT6 1499/4885PRMT1 2552/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | CARM1 988/4885PRMT6 3673/4885PRMT1 2565/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | CARM1 1209/4885PRMT6 1686/4885PRMT1 1160/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | CARM1 263/4885PRMT6 747/4885PRMT1 477/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | CARM1 871/4885PRMT6 1076/4885PRMT1 1270/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | CARM1 1209/4885PRMT6 1686/4885PRMT1 1160/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | CARM1 4595/4885PRMT6 2648/4885PRMT1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.